Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 2, keine Gesamtzahl für „Lumykras“
Suchtreffer
Begriffe & Kennungen
Lumykras · 4.5 · In vitro studies indicate that sotorasib is metabolised by cytochrome P450 (CYP) 2C8, CYP3A4, and CYP3A5, and
Eintrag öffnenLumykras · 4.5 · Strong CYP3A4 inducers Co-administration of sotorasib with multiple doses of a strong CYP3A4 inducer (rifampic
Eintrag öffnenLumykras · 4.5 · Under fasted conditions, co-administration of multiple doses of omeprazole with a single dose of 960 mg sotora
Eintrag öffnenLumykras · 4.5 · Under fed conditions (standard-calorie moderate-fat meals), co-administration of multiple doses of omeprazole
Eintrag öffnenLumykras · 4.5 · When LUMYKRAS is co-administered with a BCRP substrate, including but not limited to lapatinib, methotrexate,
Eintrag öffnenLumykras · 4.6 Fertility, pregnancy and lactation · 1
Eintrag öffnenLumykras · 4.8 Undesirable effects · 1
Eintrag öffnenLumykras · 4.8 · 8 Tabulated list of adverse reactions
Eintrag öffnenLumykras · 4.8 · 9 Description of selected adverse reactions
Eintrag öffnenLumykras · 4.8 · Adverse drug reactions (ADRs) described in table 3 reflect exposure to sotorasib 960 mg once daily as monother
Eintrag öffnenLumykras · 4.8 · Adverse reactions reported in LUMYKRAS clinical studies are displayed in table 3 below. Frequency categories a
Eintrag öffnenLumykras · 4.8 · Elderly In clinical studies, no overall differences in safety or efficacy were observed between elderly patien
Eintrag öffnenLumykras · 4.8 · Elevated liver enzymes In clinical studies, transient elevations of serum transaminases were observed (see sec
Eintrag öffnenLumykras · 4.8 · ILD/pneumonitis In clinical studies, among 740 patients who received LUMYKRAS 960 mg once daily as monotherapy
Eintrag öffnenLumykras · 4.8 · MedDRA system Very common Common Uncommon organ class (≥ 1/10) (≥ 1/100 to (≥ 1/1 000 to < 1/10) < 1/100) Bloo
Eintrag öffnenLumykras · 4.8 · Renal and urinary Renal disorders impairment Renal failure Chronic kidney disease Acute kidney injury Musculos
Eintrag öffnenLumykras · 4.8 · Reporting of suspected adverse reactions
Eintrag öffnenLumykras · 4.8 · Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows con
Eintrag öffnenLumykras · 4.8 · Summary of the safety profile
Eintrag öffnenLumykras · 4.8 · Table 3. Adverse reactions
Eintrag öffnen